Document:

Exhibit 10.12

 

 

PROMISSORY NOTE

 

	$40,000.00	September 30, 2020

 

	BORROWER:	Cingulate Therapeutics, LLC

 

	 	Address: 	1901 W. 47th Place
	 	Municipality: 	Kansas City
	 	County & State: 	Johnson County, Kansas
	 	Zip: 	66205
	 	 	 
	 	(hereinafter “Borrower”) is borrowing money from

 

	LENDER: 	Matthew Brams

 

	 	Address: 	[**]
	 	Municipality: 	[**]
	 	County & State: 	[**]
	 	Zip: 	[**]
	 	 	 
	 	(hereinafter “Lender”).

 

The words Borrower and Lender include all borrowers and all lenders under
this Note. The Lender and any other holder of this Note may transfer this Note. The word Lender includes the original Lender and anyone
who takes this Note by transfer.

 

	 1.	BORROWER’S PROMISE TO PAY:

 

In return for this loan, the Borrower promises to pay to the Lender the
sum of Forty Thousand ($40,000.00) Dollars (hereinafter “Principal”) with interest provided in Paragraph 2 from the date of
this Note until the Note is paid in full, subject to the Borrower’s ability as provided in the Agreement to convert the outstanding
Principal and accrued interest into Cingulate Therapeutics, LLC (hereinafter “Cingulate”) equity as set forth in Paragraph
5 by and between the Borrower and the Lender.

 

 

    	 

    	 

    

 

 

	2.	INTEREST:

 

The Borrower shall pay simple interest on the unpaid principal at the annual
rate of eight (8%) percent (the “Agreed Interest Rate”) from July 31, 2020 until the Principal is paid in full (hereinafter,
“Interest”). Interest shall be charged and calculated on the actual number of days elapsed over a 365-day year. The Borrower
shall pay the Principal and Interest at the earlier of the pay-off date or the conversion date of this Note.

 

	3.	PAYMENTS:

 

(a) The Borrower shall pay Principal and accrued Interest
based upon the Agreed Interest Rate as set forth in Paragraph 2. The Borrower will pay the accrued Interest either upon (i) Full Payment
as set forth in Paragraph 4 or (ii) conversion as set forth in Paragraph 5.

 

(b) All payments will be made to the Lender at the
address shown above or to a different place, if requested by the Lender in writing.

 

	4.	FULL PREPAYMENT:

 

The Borrower may repay the entire unpaid Principal and accrued Interest
at any time before it is due. This is known as full prepayment. No penalty shall be charged. The Lender will consider the Note “Paid
in Full” if the Lender receives:

 

(a) a total of Forty Thousand ($40,000.00) Dollars plus accrued Interest
by September 30, 2021, or

 

(b) the entire unpaid Principal and accrued Interest is converted into
Cingulate equity as set forth in Paragraph 5.

 

	5.	CONVERSION TO UNITS IN LIEU OF PAYMENT IN FULL:

 

Lender shall give thirty (30) days’ notice of its desire to
convert the entire unpaid Principal and accrued Interest into Preferred Units of Cingulate (hereinafter “Units”) at a
Twenty-Five (25%) Percent discount to the offered Unit price at the time of conversion. In order to exercise, the Lender
has to (a) request in writing and (b) forgive the entire unpaid Principal and accrued Interest. Borrower will then transfer the
Units to Lender as per the rules of the governing Operating Agreement.

 

	6.	LENDER’S RIGHT OF ACCELERATION:

 

The Lender may declare the unpaid Principal and accrued Interest under
this Note due immediately for certain cause. This right is called acceleration. The cause is:

 

(a) the failure of the Borrower to make any agreed
upon payments of Principal or accrued Interest under this Note within fifteen (15) days after its due date and such failure is not cured
within thirty (30) days after written notice from the Lender to the Borrower, or

 

(b) the occurrence of any event, under the current
Operating Agreement, that would cause the dissolution of the Company or that would make it unlawful for the business of the Company to
be continued.

 

The Lender’s failure to accelerate for any cause shall not prevent
the Lender from doing so for a later cause.

 

	7.	WAIVER OF FORMAL ACTS:

 

The Lender is not required to do any of the following before enforcing
the Lender’s rights under this Note:

 

(a) To demand payment of amounts due (known as Presentment)

 

(b) To give notice that amounts due have not been paid
(known as Notice of Dishonor), and

 

(c) To obtain an official certificate of nonpayment
(known as a Protest).

 

	8.	CHANGE:

 

This Note cannot be changed except in writing signed by the Borrower and
the Lender.

 

	9.	COST OF COLLECTION:

 

If the Lender has to consult an attorney, or go to court, or if the Borrower
fails to comply with the terms of this Promissory Note, the Borrower will pay all collection costs, plus reasonable lawyer’s fees.

 

	10.	GOVERNING LAW:

 

This Promissory Note has been executed in the State of Delaware and is
to be construed and enforced according to and governed by the Laws of the State of Delaware.

 

	11.	ALIENATION:

 

In the event substantially all the property securing this Note shall during
the term of this loan be sold or transferred in any manner, then at the option of the Lender, the loan shall be immediately due and payable
in full.

 

 

    	 

    	 

    

  

 

	12.	SIGNATURE:

 

The Borrower agrees to the terms of this Note by signing below.

 

IN WITNESS WHEREOF, the parties have executed this Agreement as
of the date first set forth above.

 

	 	 	BORROWER
	 	 	Cingulate Therapeutics, LLC
	 	 	 	 
	 	 	By:	/s/Craig S. Gilgallon, Esq.
	 	 	 	Craig S. Gilgallon
	 	 	 	General Counsel
	 	 	 	 
	 	 	LENDER
	 	 	 	 
	 	 	By:	/s/ Matt Brams
	 	 	 	Matt BramsExhibit
10.13

 

 

April
28, 2021

 

	Dr.
    Matthew Brams	REVISED
	[**]	 
	[**]	 

 

Dear
Dr. Brams,

 

The
undersigned parties to Promissory Notes dated February 26, 2020 and September 30, 2020 (jointly, the “Notes”), by and
between Matthew Brams (“Lender”), and Cingulate Therapeutics LLC (“Borrower”), for a total principle of
$354,000.00 (previously, and partially repaid by the Borrower), hereby mutually agree to amend said Notes to change both Paid in Full
dates to “February 24, 2022”. All other terms of the Contract shall remain in full force and effect.

 

Borrower
agrees to pay penalties, tax and interest that accrue as a result of this loan until Lender’s balance is paid in full. If
Lender receives a notice from the IRS regarding this debt, Lender must contact us immediately. Lender will use “best efforts
to avoid penalties and interest.

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.

 

	BORROWER	 	LENDER
    
	Cingulate
    Therapeutics, LLC	 	 
	 	 	 	 	 
	By:	/s/Craig
    S. Gilgallon, Esq.	 	By:	/s/
    Matt Brams
	 	Craig
    S. Gilgallon	 	 	Matt Brams
	 	General
    CounselExhibit 10.14

 

 

PROMISSORY NOTE

 

	$100,000.00	July 25, 2020

 

	BORROWER:	Cingulate Therapeutics, LLC

 

	 	Address: 	1901 W. 47th Place
	 	Municipality: 	Kansas City
	 	County & State: 	Johnson County, Kansas
	 	Zip: 	66205
	 	 	 
	 	(hereinafter “Borrower”) is borrowing money from

 

	LENDER: 	Raul Silva

 

	 	Address: 	[**]
	 	Municipality: 	[**]
	 	County & State: 	[**]
	 	Zip: 	[**]
	 	 	 
	 	(hereinafter “Lender”).

 

The words Borrower and Lender include all borrowers and all lenders under
this Note. The Lender and any other holder of this Note may transfer this Note. The word Lender includes the original Lender and anyone
who takes this Note by transfer.

 

	 1.	BORROWER’S PROMISE TO PAY:

 

In return for this loan, the Borrower promises to pay to the Lender the
sum of One Hundred Thousand ($100,000.00) Dollars (hereinafter “Principal”) with interest provided in Paragraph 2 from the
date of this Note until the Note is paid in full, subject to the Borrower’s ability as provided in the Agreement to convert the
outstanding Principal and accrued interest into Cingulate Therapeutics, LLC (hereinafter “Cingulate”) equity as set forth
in Paragraph 5 by and between the Borrower and the Lender.

 

 

    	 

    	 

    

 

 

	2.	INTEREST:

 

The Borrower shall pay simple interest on the unpaid principal at the annual
rate of eight (8%) percent (the “Agreed Interest Rate”) from July 25, 2020 until the Principal is paid in full (hereinafter,
“Interest”). Interest shall be charged and calculated on the actual number of days elapsed over a 365-day year. The Borrower
shall pay the Principal and Interest at the earlier of the pay-off date or the conversion date of this Note.

 

	3.	PAYMENTS:

 

(a) The Borrower shall pay Principal and accrued Interest
based upon the Agreed Interest Rate as set forth in Paragraph 2. The Borrower will pay the accrued Interest either upon (i) Full Payment
as set forth in Paragraph 4 or (ii) conversion as set forth in Paragraph 5.

 

(b) All payments will be made to the Lender at the
address shown above or to a different place, if requested by the Lender in writing.

 

	4.	FULL PREPAYMENT:

 

The Borrower may repay the entire unpaid Principal and accrued Interest
at any time before it is due. This is known as full prepayment. No penalty shall be charged. The Lender will consider the Note “Paid
in Full” if the Lender receives:

 

(a) a total of One Hundred Thousand ($100,000.00) Dollars plus accrued Interest
by July 24, 2021, or

 

(b) the entire unpaid Principal and accrued Interest is converted into
Cingulate equity as set forth in Paragraph 5.

 

	5.	CONVERSION TO UNITS IN LIEU OF PAYMENT IN FULL:

 

Lender shall give thirty (30) days’ notice of its desire to
convert the entire unpaid Principal and accrued Interest into Preferred Units of Cingulate (hereinafter “Units”) at a
Twenty-Five (25%) Percent discount to the offered Unit price at the time of conversion. In order to exercise, the Lender
has to (a) request in writing and (b) forgive the entire unpaid Principal and accrued Interest. Borrower will then transfer the
Units to Lender as per the rules of the governing Operating Agreement.

 

	6.	LENDER’S RIGHT OF ACCELERATION:

 

The Lender may declare the unpaid Principal and accrued Interest under
this Note due immediately for certain cause. This right is called acceleration. The cause is:

 

(a) the failure of the Borrower to make any agreed
upon payments of Principal or accrued Interest under this Note within fifteen (15) days after its due date and such failure is not cured
within thirty (30) days after written notice from the Lender to the Borrower, or

 

(b) the occurrence of any event, under the current
Operating Agreement, that would cause the dissolution of the Company or that would make it unlawful for the business of the Company to
be continued.

 

The Lender’s failure to accelerate for any cause shall not prevent
the Lender from doing so for a later cause.

 

	7.	WAIVER OF FORMAL ACTS:

 

The Lender is not required to do any of the following before enforcing
the Lender’s rights under this Note:

 

(a) To demand payment of amounts due (known as Presentment)

 

(b) To give notice that amounts due have not been paid
(known as Notice of Dishonor), and

 

(c) To obtain an official certificate of nonpayment
(known as a Protest).

 

	8.	CHANGE:

 

This Note cannot be changed except in writing signed by the Borrower and
the Lender.

 

	9.	COST OF COLLECTION:

 

If the Lender has to consult an attorney, or go to court, or if the Borrower
fails to comply with the terms of this Promissory Note, the Borrower will pay all collection costs, plus reasonable lawyer’s fees.

 

	10.	GOVERNING LAW:

 

This Promissory Note has been executed in the State of Delaware and is
to be construed and enforced according to and governed by the Laws of the State of Delaware.

 

	11.	ALIENATION:

 

In the event substantially all the property securing this Note shall during
the term of this loan be sold or transferred in any manner, then at the option of the Lender, the loan shall be immediately due and payable
in full.

 

 

    	 

    	 

    

  

 

	12.	SIGNATURE:

 

The Borrower agrees to the terms of this Note by signing below.

 

IN WITNESS WHEREOF, the parties have executed this Agreement as
of the date first set forth above.

 

	 	 	BORROWER
	 	 	Cingulate Therapeutics, LLC
	 	 	 	 
	 	 	By:	/s/Craig S. Gilgallon, Esq.
	 	 	 	Craig S. Gilgallon
	 	 	 	General Counsel
	 	 	 	 
	 	 	LENDER
	 	 	 	 
	 	 	By:	/s/ Raul Silva
	 	 	 	Raul Silva, MD

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]